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A B S T R A C T  
 
Objective: To compare the effectiveness of topical and oral Nifedipine in the treatment of chronic anal fissure. 
Patients and Methods: In this randomized control trial total of 124 patients with chronic anal fissure (CAF) were 
selected through OPD and divided randomly into two equal groups. In Group A the topical Nifedipine (2%) was applied, 
while in Group B the oral Nifedipine 10mg TDS was used. Both groups were compared in terms of pain and healing 
measured one month after starting treatment. 
Results: Mean age of the patients was 38.81±11.81 years. In both groups there was statistically significant difference 
for the age but no difference was found regarding gender and baseline visual analogue scale. Group A had better 
healing rate and pain relieve as compared to Group B. There was no difference between groups regarding the 
effectiveness of treatment. 
Conclusion: The topical Nifedipine has better healing effects as compared to the oral Nifedipine. The oral form is better 
in relieving pain after one month of treatment. There was no difference between oral and topical form in terms of overall 
effectiveness. 
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I n t r o d u c t i o n  
 
Anal fissure is one of the most common and painful 
proctologic disease in general surgery. It occurs mostly 
between the second and fourth decades of life with a 
lifetime incidence of 11%.1 Frequency of anal fissure is 
approximately equal between men and women.1 Up to 
11% of women develop this condition after childbirth. 
Approximately 90% of anal fissures in both men and 
women are located posteriorly in the midline. Anterior 
fissures occur in 10% of patients and is more common in 
women.2 Less than 1% of fissures are located off a 
midline position or is multiple in number.3 Raised resting 
sphincter pressure leads to relative ischemia especially in 
posterior midline ulceration, which results in persistence 
of internal sphincter hypertonia.4 Lateral internal 
sphincterotomy (LIS) is a surgical treatment, considered 
as the ‘gold standard’ therapy for chronic anal fissure5 
and less than 10% long term recurrence6 but associated 
with postoperative incontinence in 30% (or even more) 
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patients which can become permanent.7 Most previous 
national and international researches were based on the 
efficacy of topical agents in anal fissure management. 
Topical CCBs (Calcium Channel Blockers) have been  
shown to be better than both lignocaine ointment and 
hydrocortisone cream.7 Usage of oral Nifedipine was 
suggested in some studies for anal fissure therapy.8 
Topical Nifedipine is better in terms of wound healing for 
treatment of anal fissure as compared to oral Nifedipine 
whereas oral therapy is better in terms of pain reduction.4 
Since no national trial was found comparing the two forms 
of Nifedipine and international data is conflicting in 
support of both forms of treatment. This trial was 
conducted to compare topical Nifedipine with oral 
Nifedipine in chronic anal fissure in terms of healing and 
pain relief after 1 month in our population so that better 
treatment option could be adopted which would help in 
decreasing morbidity and hospital visits. 
P a t i e n t s  a n d  M e t h o d s  
This randomized control trial was conducted at 
Department of Surgery PAEC General Hospital 
Islamabad. Duration of the study was 6 months (20 
December 2015 to 20 June 2016). Total calculated 
sample size was 124 patients, 62 in each group. Sample 
size was calculated through WHO sample size calculator 
by using 5% level of significance, 80% power of test, 95% 
confidence level, 49.5% anticipated population mean pain 
score (P1) and 73.3% anticipated target population mean 
pain score (P2).4 Both male and female patients, who 
presented with anal fissure having age range between 18 
to 60 years and baseline pain score ≥ 4 on VAS were 
included in study. Patients with history of sexually 
transmitted disease (STDs), tuberculosis, irritable bowel 
disease or anal cancer, presence of medical related 
problems such as diabetes mellitus, migraine and 
cardiovascular diseases, pregnancy and lactation, 
hypersensitivity to nifedipine or calcium channel blockers 
and cirrhosis were excluded from the study. 
After taking the ethical approval, all the patients fulfilling 
the selection criteria were included in the study. Informed 
written consent was taken and patients were randomly 
divided into two equal groups, A & B. Randomization was 
done through lottery method. In group A, patients were 
prescribed to apply topical nifedipine cream (2%) at the 
anal margin 8 hourly. Patients in the second group were 
given 10 mg oral nifedipine TDS, for four weeks. All  
 
patients were advised to increase their intake of fiber and 
usage of sitz bath for 10-15 minutes, 2-3 times daily. On 
the first visit and follow-up visit at 4th week, wound 
healing and pain relief were recorded on Performa. For 
pain measurement, a visual analogue scale was devised 
between 0 and 10. Patients were asked to give 0 point to 
no pain and 10 for the worst pain they ever experienced. 
Wound healing was assessed by naked eye examination 
of wound for the development of granulation tissue and 
re-epitheliazation of the wound. Overall effectiveness was 
assessed by patient feedback in terms of no pain while 
passing stool and on local inspection of wound healing on 
follow up.  
All the data was entered and analyzed using statistical 
package for social sciences (SPSS version 17). Means 
and standard deviations were presented for numerical 
values i.e., age and visual analogue scores for pain. 
Frequency and percentages were presented for 
categorical data like gender and wound healing. To 
compare the proportions of the patients with effectiveness 
in both the groups, Chi square test was applied. p< 0.05 
was considered statistically significant.  
R e s u l t s  
Out of 124 patients, 60(48.4%) were male and 64 (51.6%) 
were female patients. Mean age of the patients was 38.81 
± 11.815 years. The baseline pain score was 5.97 ± 1.41 
at the start of the treatment.  When the baseline pain 
scores were compared between groups at start of the 
treatment, then there was no statistically significant 
difference between groups (Table 1). At the end of one 
month, pain was relieved (VAS ≤ 2) in 59 patients 
(47.6%). Healing was observed in 64 patients (51.6%). 
Overall, the treatment was effective in 28 patients  
Table 1: Baseline VAS score comparison between 
groups (n=124) 
Group Pain score (mean ± SD) p-value 
A 6.02 ± 1.38 0.704 
B 5.92 ± 1.44 
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(22.6%). Both the groups were compared regarding the 
pain and healing at the end of one month. Regarding pain 
and healing, Group A had significantly better effects as 
compared to Group B. There was no significant difference 
between groups when the effectiveness of the treatment 
was compared (Table 2). 
D i s c u s s i o n  
Chronic anal fissure (CAF) is a condition when the anal 
fissure is there for more than six weeks at anoderm. Most 
of the time acute stage is usually treated with 
conservative management but the chronic condition 
usually needs surgical intervention. Various drugs used 
have variable results in terms of symptoms and healing 
rates.9 Glyceryl trinitrate (GTN) is smooth muscle relaxant 
and vasodilator and it is more effective when it is used 
topically for treatment of CAF.10,11 CCBs are good 
alternative for those who did not tolerate the GTN. CCBs 
can be used topically as well as orally. The CCBs have 
some side effects like headache, dizziness, itching and 
burning at the site of application.12, 13 
The local injection of the botox toxin is effective in short 
term for the treatment of CAF.14 Cook, T. A., et al showed 
that the resting anal pressure is reduced by taking the 
Nifedipine orally and it results in the quick healing of 
CAF.15 Similar results were shown by the other studies 
later on.16,17  Ho, K. S. and Y. H compared the LIS and 
oral Nifedipine and the results showed that LIS was 
significantly more effective than oral Nifedipine in 
providing pain relief (P = 0.004) and better patient 
satisfaction (P = 0.020) at 4 weeks.18 Another study 
showed that the LIS and topical form of Nifedipine 
showed similar results in terms of healing and pain 
relief.19 Golfam, F., et al. concluded that topical Nifedipine 
has a superior role for anal fissure treatment with higher 
healing rate and lower side effects as compared to oral 
one.4 
C o n c l u s i o n  
The topical Nifedipine is more effective in relieving the 
pain and healing as compared to oral form in CAF. 
Multicenter research work on large scale is recommended 
to evaluate the oral and topical forms of Nifedipine for the 
treatment of CAF. 
R e f e r e n c e s  
1. Altomare DF, Binda GA, Canuti S, Landolfi V, Trompetto 
M, Villani RD. The management of patients with primary 
chronic anal fissure: a position paper. Tech Coloproctol. 
2011;15(2):135-41. 
2. Zaghiyan KN, Fleshner P. Anal fissure. Clin Colon Rectal 
Surg. 2011;24(1):22-30. 
3. Agrawal V, Kaushal G, Gupta R. Randomized controlled 
pilot trial of nifedipine as oral therapy vs. topical application 
in the treatment of fissure-in-ano. Am J Surg. 
2013;206(5):748-51. 
4. Golfam F, Golfam P, Golfam B, Pahlevani P. Comparison 
of topical nifedipine with oral nifedipine for treatment of 
anal fissure: a randomized controlled trial. Iran Red 
Crescent Med J. 2014;16(8):e13592. 
5. Perry WB, Dykes SL, Buie WD, Rafferty JF, Standards 
Practice Task Force of the American Society of C, Rectal 
S. Practice parameters for the management of anal 
fissures (3rd revision). Dis Colon Rectum. 
2010;53(8):1110-5. 
6. Aivaz O, Rayhanabad J, Nguyen V, Haigh PI, Abbas M. 
Botulinum toxin A with fissurectomy is a viable alternative 
to lateral internal sphincterotomy for chronic anal fissure. 
Am Surg. 2009;75(10):925-8. 
7. Madalinski MH. Identifying the best therapy for chronic 
anal fissure. World J Gastrointest Pharmacol Ther. 
2011;2(2):9-16. 95.  
8. Golfam F, Golfam P, Khalaj A, Sayed Mortaz SS. The 
effect of topical nifedipine in treatment of chronic anal 
fissure. Acta Med Iran. 2010;48(5):295-9. 
9. Van Outryve M. Physiopathology of the anal fissure. Acta 
Chir Belg. 2006;106(5):517-8. 
Table 2: Comparison of outcomes between groups at 
end of month (n=124) 
 Groups Status p-
value 
Yes 
N (%) 
No 
N (%) 
 
Healing 
Group A 40(64.5) 22(35.5)  
0.004 Group B 24(38.7) 38(61.3) 
 
Pain 
Group A 36(58.1) 26(41.9)  
0.019 Group B 23(37.1) 39(62.9) 
Overall 
Effectivenes
s (pain relief 
+ healing ) 
Group A 13(21) 49(79)  
0.668 
Group B 15(24.2) 47(75.8) 
                            91 JIMDC  2018  91 
10. Garrido R, Lagos N, Lagos M, Rodriguez-Navarro AJ, 
Garcia C, Truan D, et al. Treatment of chronic anal fissure 
by gonyautoxin. Colorectal Dis. 2007;9(7):619-24. 
11. Husberg B, Malmborg P, Strigard K. Treatment with 
botulinum toxin in children with chronic anal fissure. Eur J 
Pediatr Surg. 2009;19(5):290-2. 
12. Hashmi F, Siddiqui FG. Diltiazem (2%) versus glyceryl 
trinitrate cream (0.2%) in the management of chronic anal 
fissure. J Coll Physicians Surg Pak. 2009;19(12):750-3. 
13. Jawaid M, Masood Z, Salim M. Topical diltiazem 
hydrochloride and glyceryl trinitrate in the treatment of 
chronic anal fissure. J Coll Physicians Surg Pak. 
2009;19(10):614-7. 
14. Piccinni G, Poli E, Angrisano A, Sciusco A, Testini M. 
Botox for chronic anal fissure: is it useful? A clinical 
experience with mid-term follow-up. Acta Biomed. 
2009;80(3):238-42. 
15. Cook TA, Humphreys MM, Mc CMNJ. Oral nifedipine 
reduces resting anal pressure and heals chronic anal 
fissure. Br J Surg. 1999;86(10):1269-73. 
16. Brisinda G, Maria G. Oral nifedipine reduces resting anal 
pressure and heals chronic anal fissure. Br J Surg. 
2000;87(2):251. 
17. Agaoglu N, Cengiz S, Arslan MK, Turkyilmaz S. Oral 
nifedipine in the treatment of chronic anal fissure. Dig 
Surg. 2003;20(5):452-6. 
18. Ho KS, Ho YH. Randomized clinical trial comparing oral 
nifedipine with lateral anal sphincterotomy and tailored 
sphincterotomy in the treatment of chronic anal fissure. Br 
J Surg. 2005;92(4):403-8. 
19. Katsinelos P, Papaziogas B, Koutelidakis I, Paroutoglou G, 
Dimiropoulos S, Souparis A, et al. Topical 0.5% nifedipine 
vs. lateral internal sphincterotomy for the treatment of 
chronic anal fissure: long-term follow-up. Int J Colorectal 
Dis. 2006;21(2):179-83. 
 
 
 
 
 
 
 
